Gene symbol |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
AK082687
|  |
AK082687 |
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230086D05 product:unclassifiable, full insert sequence [AK082687] |
KLA | 1.00 |
.95 |
1.04 |
.95 |
1.01 |
1.01 |
1.14 |
| ATP | 1.00 |
.96 |
1.03 |
1.05 |
.92 |
1.02 |
.89 |
| KLA/ATP | 1.01 |
1.09 |
1.04 |
1.03 |
1.05 |
1.01 |
1.02 |
|
Araf |  |
NM_009703 |
v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] |
KLA | .87 |
.80 |
.89 |
.93 |
1.10 |
1.19 |
1.16 |
| ATP | 1.09 |
1.11 |
1.19 |
1.18 |
.78 |
.53 |
1.18 |
| KLA/ATP | 1.00 |
.95 |
.99 |
.93 |
.63 |
.55 |
1.27 |
|
BE980448
|  |
BE980448 |
gb|UI-M-BG2-bci-g-09-0-UI.s1 NIH_BMAP_MSC_S1 Mus musculus cDNA clone UI-M-BG2-bci-g-09-0-UI 3. [BE980448] |
KLA | .97 |
.93 |
.89 |
.98 |
.96 |
.95 |
.93 |
| ATP | 1.02 |
1.03 |
.99 |
.97 |
.99 |
.97 |
1.01 |
| KLA/ATP | .91 |
.88 |
.84 |
.89 |
.93 |
.96 |
.91 |
|
Braf |  |
NM_139294 |
Braf transforming gene (Braf), mRNA [NM_139294] |
KLA | 1.52 |
1.57 |
1.55 |
1.33 |
1.83 |
1.52 |
1.60 |
| ATP | 1.08 |
1.17 |
1.02 |
1.37 |
.95 |
1.15 |
.95 |
| KLA/ATP | 1.64 |
1.69 |
1.39 |
1.51 |
1.04 |
1.31 |
1.26 |
|
Cacna1a |  |
NM_007578 |
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit (Cacna1a), mRNA [NM_007578] |
KLA | .71 |
.66 |
.61 |
.63 |
.60 |
.71 |
.72 |
| ATP | 1.07 |
1.04 |
.89 |
1.08 |
.71 |
.56 |
.75 |
| KLA/ATP | .71 |
.72 |
.85 |
.69 |
.64 |
.63 |
.68 |
|
Crhr1 |  |
NM_007762 |
corticotropin releasing hormone receptor 1 (Crhr1), mRNA [NM_007762] |
KLA | 1.00 |
1.05 |
1.06 |
1.05 |
1.06 |
1.06 |
1.05 |
| ATP | 1.04 |
.97 |
1.03 |
1.06 |
1.09 |
1.07 |
1.03 |
| KLA/ATP | 1.08 |
1.10 |
1.05 |
1.11 |
1.10 |
1.05 |
1.13 |
|
Gna11 |  |
NM_010301 |
guanine nucleotide binding protein, alpha 11 (Gna11), mRNA [NM_010301] |
KLA | .62 |
.65 |
.69 |
.79 |
.94 |
1.00 |
.96 |
| ATP | 1.00 |
.94 |
.63 |
.53 |
.79 |
1.13 |
1.22 |
| KLA/ATP | .64 |
.60 |
.56 |
.55 |
.81 |
1.16 |
1.18 |
|
Gna12 |  |
M63659 |
gb|Mouse G-alpha-12 protein mRNA, complete cds [M63659] |
KLA | .48 |
.48 |
.49 |
.40 |
.44 |
.59 |
.60 |
| ATP | 1.08 |
1.15 |
1.00 |
1.39 |
1.02 |
.65 |
.73 |
| KLA/ATP | .52 |
.50 |
.51 |
.52 |
.56 |
.66 |
.52 |
|
Gna13 |  |
NM_010303 |
guanine nucleotide binding protein, alpha 13 (Gna13), mRNA [NM_010303] |
KLA | 1.96 |
2.10 |
2.12 |
1.85 |
2.36 |
2.02 |
1.54 |
| ATP | 1.04 |
1.13 |
1.19 |
3.56 |
6.50 |
2.32 |
1.44 |
| KLA/ATP | 2.17 |
2.07 |
1.67 |
3.72 |
6.89 |
3.91 |
2.27 |
|
Gnai1 |  |
NM_010305 |
guanine nucleotide binding protein (G protein), alpha inhibiting 1 (Gnai1), mRNA [NM_010305] |
KLA | .95 |
1.01 |
1.01 |
1.00 |
1.09 |
1.10 |
1.08 |
| ATP | 1.06 |
1.06 |
.99 |
1.15 |
1.02 |
.94 |
.99 |
| KLA/ATP | 1.02 |
1.04 |
.99 |
1.16 |
1.01 |
1.02 |
1.13 |
|
Gnai2 |  |
NM_008138 |
guanine nucleotide binding protein (G protein), alpha inhibiting 2 (Gnai2), mRNA [NM_008138] |
KLA | .74 |
.79 |
.82 |
.74 |
.91 |
.97 |
1.10 |
| ATP | 1.07 |
1.16 |
.78 |
1.12 |
.78 |
.48 |
.82 |
| KLA/ATP | .91 |
.81 |
.53 |
.80 |
.60 |
.68 |
.87 |
|
Gnai3 |  |
NM_010306 |
guanine nucleotide binding protein (G protein), alpha inhibiting 3 (Gnai3), mRNA [NM_010306] |
KLA | 1.23 |
1.24 |
1.14 |
1.06 |
.99 |
1.15 |
1.09 |
| ATP | .96 |
.93 |
.86 |
.64 |
1.34 |
2.02 |
1.35 |
| KLA/ATP | 1.20 |
1.24 |
.97 |
.76 |
1.21 |
1.62 |
1.17 |
|
Gnao1 |  |
NM_001113384 |
guanine nucleotide binding protein, alpha O (Gnao1), transcript variant B, mRNA [NM_001113384] |
KLA | .95 |
.98 |
1.03 |
1.00 |
1.02 |
1.02 |
.99 |
| ATP | .95 |
1.02 |
1.01 |
1.08 |
.99 |
.97 |
.95 |
| KLA/ATP | 1.05 |
1.04 |
1.10 |
.99 |
1.01 |
.98 |
1.03 |
|
Gnao1 |  |
NM_010308 |
guanine nucleotide binding protein, alpha O (Gnao1), transcript variant A, mRNA [NM_010308] |
KLA | .98 |
.96 |
1.00 |
.97 |
.96 |
.97 |
1.01 |
| ATP | 1.12 |
.99 |
1.05 |
.87 |
.97 |
1.02 |
1.01 |
| KLA/ATP | .93 |
1.00 |
.99 |
1.01 |
1.05 |
1.07 |
.98 |
|
Gnaq |  |
NM_008139 |
guanine nucleotide binding protein, alpha q polypeptide (Gnaq), mRNA [NM_008139] |
KLA | .82 |
.82 |
.69 |
.64 |
.60 |
.55 |
.55 |
| ATP | 1.06 |
1.02 |
.87 |
.67 |
.50 |
.66 |
.57 |
| KLA/ATP | .82 |
.79 |
.66 |
.55 |
.41 |
.33 |
.48 |
|
Gnas |  |
AF107847 |
neuroendocrine-specific Golgi protein p55 isoform 1 (XLalphas) alternatively spliced mRNA, complete cds. [AF107847] |
KLA | 1.04 |
.94 |
1.00 |
1.05 |
1.04 |
.98 |
1.00 |
| ATP | .98 |
.97 |
.96 |
1.00 |
.99 |
.98 |
1.02 |
| KLA/ATP | 1.04 |
1.02 |
.96 |
.95 |
1.01 |
.96 |
1.01 |
|
Gnas |  |
AK017423 |
10 days neonate head cDNA, RIKEN full-length enriched library, clone:5530400H20 product:novel noncoding RNA overlapping the exon 1A, 1 and 2 of Gnas, full insert sequence. [AK017423] |
KLA | .85 |
1.08 |
.97 |
.92 |
1.05 |
1.03 |
1.08 |
| ATP | .99 |
1.30 |
2.11 |
1.73 |
1.23 |
1.01 |
1.02 |
| KLA/ATP | .96 |
1.06 |
1.58 |
1.34 |
1.29 |
1.05 |
.91 |
|
Gnas |  |
NM_001077510 |
GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus (Gnas), transcript variant 8, mRNA [NM_001077510] |
KLA | .99 |
1.03 |
.97 |
.91 |
1.03 |
.95 |
.97 |
| ATP | 1.04 |
1.19 |
1.15 |
1.61 |
1.24 |
.91 |
1.00 |
| KLA/ATP | 1.06 |
.97 |
1.01 |
1.46 |
1.04 |
.85 |
1.01 |
|
Gnas |  |
S49980 |
gb|stimulatory G protein alpha subunit {clone WC-16} [mice, whole cochlea, mRNA Partial, 356 nt]. [S49980] |
KLA | .91 |
.88 |
1.03 |
.87 |
.90 |
.84 |
1.01 |
| ATP | 1.16 |
1.22 |
1.02 |
1.55 |
1.16 |
.80 |
.99 |
| KLA/ATP | 1.01 |
1.13 |
.86 |
1.12 |
.97 |
.85 |
1.08 |
|
Gnaz |  |
NM_010311 |
guanine nucleotide binding protein, alpha z subunit (Gnaz), mRNA [NM_010311] |
KLA | 1.04 |
1.02 |
1.02 |
1.04 |
.95 |
.98 |
1.03 |
| ATP | 1.00 |
1.03 |
.98 |
1.03 |
1.08 |
1.03 |
.96 |
| KLA/ATP | 1.08 |
1.03 |
1.02 |
1.04 |
1.01 |
1.00 |
1.02 |
|
Gria1 |  |
NM_008165 |
glutamate receptor, ionotropic, AMPA1 (alpha 1) (Gria1), transcript variant 2, mRNA [NM_008165] |
KLA | .97 |
1.02 |
1.02 |
1.01 |
1.03 |
1.02 |
1.11 |
| ATP | 1.03 |
.97 |
1.05 |
1.03 |
1.01 |
1.01 |
1.01 |
| KLA/ATP | 1.02 |
.99 |
1.01 |
1.06 |
1.15 |
1.06 |
1.05 |
|
Gria2 |  |
BC048248 |
glutamate receptor, ionotropic, AMPA2 (alpha 2), mRNA (cDNA clone MGC:54603 IMAGE:6494013), complete cds. [BC048248] |
KLA | 1.00 |
1.01 |
1.05 |
1.00 |
1.03 |
.97 |
1.06 |
| ATP | .98 |
1.00 |
1.00 |
.96 |
1.03 |
1.05 |
1.04 |
| KLA/ATP | .98 |
1.08 |
.99 |
1.04 |
1.06 |
1.02 |
1.05 |
|
Gria2 |  |
NM_013540 |
glutamate receptor, ionotropic, AMPA2 (alpha 2) (Gria2), transcript variant 2, mRNA [NM_013540] |
KLA | 1.02 |
1.02 |
.98 |
1.01 |
.98 |
1.02 |
1.01 |
| ATP | .95 |
1.01 |
.95 |
.99 |
1.09 |
1.02 |
1.09 |
| KLA/ATP | 1.06 |
.92 |
.96 |
.99 |
1.00 |
1.03 |
1.00 |
|
Gria3 |  |
AK161163 |
0 day neonate head cDNA, RIKEN full-length enriched library, clone:4831401I16 product:glutamate receptor, ionotropic, AMPA3 (alpha 3), full insert sequence. [AK161163] |
KLA | 1.01 |
.96 |
.97 |
.95 |
.99 |
.84 |
.81 |
| ATP | 1.05 |
1.04 |
1.07 |
.86 |
.88 |
.84 |
.65 |
| KLA/ATP | .94 |
.95 |
1.06 |
.83 |
.79 |
.75 |
.66 |
|
Gria3 |  |
NM_016886 |
glutamate receptor, ionotropic, AMPA3 (alpha 3) (Gria3), mRNA [NM_016886] |
KLA | 1.04 |
.95 |
1.05 |
.98 |
.98 |
.97 |
.95 |
| ATP | 1.00 |
1.08 |
1.01 |
.97 |
.93 |
.98 |
.97 |
| KLA/ATP | 1.03 |
.93 |
.93 |
.98 |
.96 |
1.03 |
.89 |
|
Grid2 |  |
AK032669 |
10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:6530411F08 product:glutamate receptor, ionotropic, delta 2, full insert sequence. [AK032669] |
KLA | 1.00 |
1.02 |
1.01 |
1.01 |
1.01 |
1.01 |
1.00 |
| ATP | 1.01 |
1.01 |
.99 |
.99 |
1.01 |
1.01 |
1.00 |
| KLA/ATP | 1.02 |
1.01 |
1.01 |
1.02 |
.99 |
1.01 |
.99 |
|
Grid2 |  |
AK036230 |
16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630046P05 product:glutamate receptor, ionotropic, delta 2, full insert sequence. [AK036230] |
KLA | 1.01 |
.97 |
1.01 |
.96 |
.96 |
.96 |
1.06 |
| ATP | 1.00 |
1.01 |
1.01 |
.97 |
1.00 |
.97 |
1.03 |
| KLA/ATP | 1.02 |
1.06 |
1.02 |
.92 |
.95 |
.95 |
.99 |
|
Grm1 |  |
NM_016976 |
glutamate receptor, metabotropic 1 (Grm1), transcript variant 1, mRNA [NM_016976] |
KLA | 1.16 |
1.07 |
1.10 |
1.18 |
1.08 |
1.04 |
1.15 |
| ATP | 1.06 |
1.05 |
1.02 |
.99 |
1.00 |
1.09 |
1.02 |
| KLA/ATP | 1.04 |
1.12 |
1.06 |
1.11 |
1.10 |
1.32 |
1.35 |
|
Gsbs |  |
AF071562 |
G-substrate mRNA, complete cds. [AF071562] |
KLA | 1.01 |
.99 |
.99 |
1.00 |
1.05 |
.98 |
.98 |
| ATP | 1.02 |
1.03 |
1.04 |
1.00 |
.93 |
.93 |
.97 |
| KLA/ATP | 1.00 |
.97 |
.96 |
.88 |
1.00 |
.93 |
.97 |
|
Gsbs |  |
NM_011153 |
G substrate (Gsbs), mRNA [NM_011153] |
KLA | 1.02 |
1.09 |
.96 |
1.01 |
1.04 |
1.03 |
1.00 |
| ATP | 1.01 |
.99 |
1.02 |
1.08 |
.92 |
1.12 |
1.06 |
| KLA/ATP | 1.02 |
.91 |
1.05 |
1.01 |
1.04 |
1.01 |
1.06 |
|
Gucy1a3 |  |
NM_021896 |
guanylate cyclase 1, soluble, alpha 3 (Gucy1a3), mRNA [NM_021896] |
KLA | 1.01 |
1.01 |
1.04 |
.99 |
.99 |
.97 |
.99 |
| ATP | .99 |
1.01 |
.99 |
.99 |
.97 |
1.02 |
1.02 |
| KLA/ATP | 1.00 |
.96 |
1.00 |
.99 |
.98 |
1.04 |
.99 |
|
Gucy1b2 |  |
NM_172810 |
guanylate cyclase 1, soluble, beta 2 (Gucy1b2), mRNA [NM_172810] |
KLA | 1.02 |
1.03 |
1.03 |
1.09 |
.95 |
1.06 |
.91 |
| ATP | 1.01 |
1.03 |
1.01 |
1.08 |
.96 |
1.04 |
.90 |
| KLA/ATP | 1.04 |
1.03 |
.99 |
1.05 |
.97 |
.96 |
.84 |
|
Gucy1b3 |  |
NM_017469 |
guanylate cyclase 1, soluble, beta 3 (Gucy1b3), mRNA [NM_017469] |
KLA | .99 |
.99 |
.99 |
1.01 |
.98 |
.98 |
1.00 |
| ATP | .98 |
.98 |
.98 |
.98 |
.98 |
1.00 |
1.01 |
| KLA/ATP | .96 |
.99 |
.98 |
1.01 |
.99 |
.99 |
.99 |
|
Hras1 |  |
NM_008284 |
Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] |
KLA | .79 |
.82 |
.77 |
.82 |
.94 |
1.03 |
1.07 |
| ATP | 1.01 |
.95 |
.69 |
.83 |
.79 |
1.12 |
1.15 |
| KLA/ATP | .84 |
.77 |
.61 |
.65 |
.82 |
1.00 |
1.05 |
|
Igf1 |  |
AK050118 |
adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730016P09 product:unclassifiable, full insert sequence. [AK050118] |
KLA | .13 |
.14 |
.15 |
.16 |
.22 |
.34 |
.48 |
| ATP | 1.78 |
2.05 |
1.37 |
.72 |
.34 |
.41 |
.58 |
| KLA/ATP | .24 |
.45 |
.50 |
.24 |
.20 |
.26 |
.68 |
|
Igf1 |  |
NM_010512 |
insulin-like growth factor 1 (Igf1), transcript variant 1, mRNA [NM_010512] |
KLA | .84 |
.78 |
.76 |
.67 |
.54 |
.48 |
.59 |
| ATP | .97 |
.98 |
1.13 |
1.13 |
1.03 |
.88 |
.89 |
| KLA/ATP | .82 |
.81 |
.93 |
.86 |
.83 |
.65 |
.89 |
|
Igf1 |  |
NM_184052 |
insulin-like growth factor 1 (Igf1), transcript variant 2, mRNA [NM_184052] |
KLA | .77 |
.82 |
.76 |
.65 |
.60 |
.52 |
.69 |
| ATP | 1.01 |
1.07 |
.98 |
1.06 |
1.03 |
.78 |
.94 |
| KLA/ATP | .89 |
.86 |
.77 |
.80 |
.75 |
.65 |
.89 |
|
Igf1r |  |
NM_010513 |
insulin-like growth factor I receptor (Igf1r), mRNA [NM_010513] |
KLA | 1.32 |
1.32 |
1.08 |
.91 |
.55 |
.48 |
.45 |
| ATP | 1.03 |
1.06 |
1.06 |
1.29 |
1.31 |
1.45 |
.47 |
| KLA/ATP | 1.30 |
1.37 |
1.11 |
1.00 |
.93 |
1.02 |
.45 |
|
Itpr1 |  |
NM_010585 |
inositol 1,4,5-triphosphate receptor 1 (Itpr1), mRNA [NM_010585] |
KLA | 3.66 |
3.69 |
6.74 |
8.11 |
7.08 |
4.40 |
1.22 |
| ATP | 1.08 |
.95 |
1.19 |
.94 |
1.09 |
1.00 |
.68 |
| KLA/ATP | 3.48 |
3.58 |
5.86 |
6.03 |
4.01 |
2.31 |
.97 |
|
Itpr2 |  |
NM_019923 |
inositol 1,4,5-triphosphate receptor 2 (Itpr2), transcript variant 1, mRNA [NM_019923] |
KLA | 1.41 |
1.38 |
1.43 |
1.42 |
1.30 |
1.07 |
1.01 |
| ATP | 1.00 |
1.00 |
.97 |
.97 |
1.07 |
1.15 |
1.06 |
| KLA/ATP | 1.39 |
1.48 |
1.64 |
1.42 |
1.07 |
.83 |
.95 |
|
Itpr3 |  |
NM_080553 |
inositol 1,4,5-triphosphate receptor 3 (Itpr3), mRNA [NM_080553] |
KLA | .55 |
.51 |
.45 |
.41 |
.34 |
.34 |
.45 |
| ATP | 1.01 |
.92 |
1.02 |
.57 |
.46 |
.34 |
1.22 |
| KLA/ATP | .56 |
.48 |
.48 |
.29 |
.33 |
.27 |
.65 |
|
Kras |  |
NM_021284 |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] |
KLA | .53 |
.49 |
.40 |
.42 |
.49 |
.95 |
1.05 |
| ATP | .98 |
1.01 |
1.16 |
1.17 |
1.39 |
1.29 |
1.74 |
| KLA/ATP | .50 |
.47 |
.50 |
.56 |
1.00 |
1.24 |
1.58 |
|
LOC10004 8021 |  |
XM_001479354 |
ref|PREDICTED: Mus musculus similar to Guanine nucleotide-binding protein alpha-12 subunit (G alpha-12) (LOC100048021), mRNA [XM_001479354] |
KLA | .29 |
.29 |
.23 |
.19 |
.25 |
.43 |
.47 |
| ATP | 1.03 |
1.08 |
.94 |
.88 |
.78 |
.52 |
.59 |
| KLA/ATP | .32 |
.29 |
.20 |
.22 |
.31 |
.47 |
.36 |
|
Lyn |  |
NM_010747 |
Yamaguchi sarcoma viral (v-yes-1) oncogene homolog (Lyn), transcript variant 2, mRNA [NM_010747] |
KLA | 2.48 |
2.80 |
3.76 |
3.81 |
5.30 |
4.57 |
2.46 |
| ATP | 1.06 |
1.18 |
.82 |
.97 |
.74 |
1.45 |
1.21 |
| KLA/ATP | 2.82 |
3.16 |
2.24 |
2.87 |
1.73 |
1.80 |
2.63 |
|
Map2k1 |  |
NM_008927 |
mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] |
KLA | 1.82 |
2.00 |
2.31 |
2.03 |
2.51 |
2.20 |
1.51 |
| ATP | .99 |
1.14 |
.81 |
.87 |
.90 |
1.57 |
1.11 |
| KLA/ATP | 1.90 |
2.03 |
1.50 |
1.93 |
1.63 |
2.03 |
2.06 |
|
Map2k2 |  |
NM_023138 |
mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] |
KLA | .96 |
1.01 |
1.09 |
.99 |
1.11 |
1.15 |
1.42 |
| ATP | 1.07 |
1.05 |
.74 |
.86 |
1.04 |
1.16 |
1.21 |
| KLA/ATP | 1.14 |
1.03 |
.68 |
.78 |
.85 |
1.01 |
1.20 |
|
Mapk1 |  |
NM_001038663 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] |
KLA | .97 |
1.03 |
.93 |
.86 |
.79 |
1.01 |
1.04 |
| ATP | .96 |
1.18 |
1.01 |
1.13 |
.84 |
1.04 |
1.16 |
| KLA/ATP | .99 |
.99 |
.84 |
.87 |
.63 |
.96 |
1.26 |
|
Mapk1 |  |
NM_011949 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] |
KLA | .88 |
.80 |
.80 |
.73 |
.75 |
.76 |
.65 |
| ATP | .97 |
.96 |
1.06 |
.88 |
.90 |
.68 |
.48 |
| KLA/ATP | .82 |
.81 |
.78 |
.65 |
.64 |
.64 |
.45 |
|
Mapk3 |  |
NM_011952 |
mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] |
KLA | .81 |
.85 |
.88 |
.72 |
.79 |
.73 |
.90 |
| ATP | 1.13 |
1.30 |
.92 |
1.48 |
1.08 |
.68 |
1.03 |
| KLA/ATP | 1.01 |
1.01 |
.66 |
1.13 |
.77 |
.77 |
1.16 |
|
Mm.22094 6 |  |
27545180 |
Unknown |
KLA | 1.00 |
.93 |
.97 |
1.05 |
1.06 |
1.29 |
1.13 |
| ATP | .90 |
.94 |
1.25 |
1.18 |
.85 |
.62 |
1.20 |
| KLA/ATP | .86 |
.99 |
1.14 |
.99 |
.83 |
.70 |
1.26 |
|
Mm.27574 2 |  |
112983655 |
Unknown |
KLA | 1.35 |
1.16 |
.94 |
.85 |
.45 |
.33 |
.31 |
| ATP | .90 |
.86 |
1.17 |
1.09 |
1.18 |
1.21 |
.38 |
| KLA/ATP | 1.12 |
1.22 |
1.19 |
.91 |
.90 |
.83 |
.33 |
|
Mm.33050 7 |  |
67906182 |
Unknown |
KLA | .94 |
.98 |
.99 |
1.03 |
1.05 |
1.07 |
.98 |
| ATP | .95 |
1.02 |
.97 |
.98 |
.99 |
1.05 |
1.02 |
| KLA/ATP | 1.02 |
1.05 |
1.01 |
1.03 |
.99 |
.98 |
.97 |
|
Mm.44160 1 |  |
145966786 |
Unknown |
KLA | 1.08 |
.94 |
1.01 |
.97 |
.79 |
.78 |
.71 |
| ATP | 1.09 |
.92 |
1.10 |
.75 |
.65 |
.92 |
.69 |
| KLA/ATP | 1.01 |
.92 |
1.16 |
.81 |
.69 |
.56 |
.63 |
|
Nos1 |  |
NM_008712 |
nitric oxide synthase 1, neuronal (Nos1), mRNA [NM_008712] |
KLA | 1.01 |
1.01 |
1.02 |
.99 |
1.02 |
1.02 |
1.01 |
| ATP | 1.01 |
1.03 |
1.02 |
1.04 |
1.03 |
1.01 |
1.00 |
| KLA/ATP | 1.05 |
1.02 |
1.02 |
1.00 |
1.02 |
1.03 |
1.03 |
|
Nras |  |
NM_010937 |
neuroblastoma ras oncogene (Nras), mRNA [NM_010937] |
KLA | 1.20 |
1.22 |
1.27 |
1.20 |
1.09 |
.91 |
.84 |
| ATP | .98 |
.91 |
.69 |
.61 |
.59 |
.67 |
.78 |
| KLA/ATP | 1.22 |
1.14 |
.97 |
.79 |
.73 |
.61 |
.72 |
|
Pla2g4a |  |
NM_008869 |
phospholipase A2, group IVA (cytosolic, calcium-dependent) (Pla2g4a), mRNA [NM_008869] |
KLA | 3.93 |
4.49 |
4.86 |
6.40 |
6.44 |
3.10 |
1.68 |
| ATP | 1.13 |
1.36 |
1.27 |
1.30 |
1.02 |
5.37 |
1.47 |
| KLA/ATP | 3.64 |
4.45 |
4.76 |
7.11 |
2.96 |
4.08 |
2.60 |
|
Pla2g4b |  |
NM_145378 |
phospholipase A2, group IVB (cytosolic) (Pla2g4b), mRNA [NM_145378] |
KLA | 1.09 |
1.18 |
.95 |
1.01 |
.97 |
.97 |
.77 |
| ATP | 1.05 |
1.14 |
1.28 |
.94 |
.88 |
1.18 |
.70 |
| KLA/ATP | 1.23 |
1.43 |
1.21 |
1.02 |
1.15 |
1.16 |
.78 |
|
Pla2g4c |  |
AK145339 |
1 cell embryo 1 cell cDNA, RIKEN full-length enriched library, clone:I0C0013F18 product:weakly similar to Cytosolic phospholipase A2 gamma [Homo sapiens], full insert sequence [AK145339] |
KLA | 1.09 |
1.21 |
1.33 |
1.17 |
1.26 |
1.30 |
1.05 |
| ATP | .97 |
1.06 |
1.00 |
.98 |
.98 |
.98 |
1.05 |
| KLA/ATP | 1.19 |
1.16 |
1.18 |
1.13 |
1.04 |
1.02 |
1.06 |
|
Pla2g4c |  |
NM_001004762 |
phospholipase A2, group IVC (cytosolic, calcium-independent) (Pla2g4c), mRNA [NM_001004762] |
KLA | .93 |
1.00 |
.94 |
.93 |
.94 |
.94 |
.96 |
| ATP | .98 |
.96 |
1.13 |
.97 |
.99 |
.89 |
.96 |
| KLA/ATP | 1.01 |
1.01 |
1.07 |
1.01 |
.94 |
1.01 |
.92 |
|
Pla2g4e |  |
AK049063 |
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230096D22 product:hypothetical Lysophospholipase catalytic domain containing protein, full insert sequence. [AK049063] |
KLA | 1.03 |
1.09 |
1.01 |
1.01 |
1.06 |
.94 |
1.05 |
| ATP | 1.03 |
1.00 |
1.06 |
1.01 |
.96 |
1.05 |
1.05 |
| KLA/ATP | .98 |
1.00 |
1.01 |
.98 |
1.03 |
.95 |
1.01 |
|
Pla2g4e |  |
NM_177845 |
phospholipase A2, group IVE (Pla2g4e), mRNA [NM_177845] |
KLA | .97 |
.95 |
1.01 |
.97 |
1.02 |
1.03 |
1.05 |
| ATP | .98 |
.99 |
1.00 |
1.10 |
.98 |
1.00 |
1.02 |
| KLA/ATP | 1.05 |
.93 |
.96 |
1.03 |
1.08 |
1.05 |
.99 |
|
Pla2g4f |  |
NM_001024145 |
phospholipase A2, group IVF (Pla2g4f), mRNA [NM_001024145] |
KLA | 1.08 |
.99 |
1.04 |
1.02 |
1.04 |
.98 |
1.01 |
| ATP | .99 |
1.04 |
.99 |
1.03 |
1.12 |
1.01 |
1.25 |
| KLA/ATP | .97 |
1.04 |
1.10 |
1.06 |
1.04 |
1.03 |
1.03 |
|
Plcb1 |  |
AK129166 |
mRNA for mKIAA0581 protein [AK129166] |
KLA | 1.02 |
.98 |
.91 |
.91 |
.92 |
.95 |
.89 |
| ATP | 1.03 |
1.02 |
1.02 |
1.01 |
.90 |
1.02 |
1.04 |
| KLA/ATP | .98 |
.97 |
.91 |
.93 |
.92 |
1.01 |
1.16 |
|
Plcb1 |  |
NM_019677 |
phospholipase C, beta 1 (Plcb1), mRNA [NM_019677] |
KLA | .99 |
.94 |
.95 |
.97 |
.93 |
.92 |
.91 |
| ATP | 1.00 |
.96 |
.99 |
.95 |
.99 |
1.03 |
.98 |
| KLA/ATP | .93 |
.96 |
.94 |
.93 |
.87 |
1.00 |
1.06 |
|
Plcb2 |  |
NM_177568 |
phospholipase C, beta 2 (Plcb2), mRNA [NM_177568] |
KLA | .70 |
.68 |
.64 |
.67 |
.65 |
.76 |
.88 |
| ATP | .95 |
.94 |
1.04 |
.94 |
.72 |
.57 |
1.19 |
| KLA/ATP | .69 |
.68 |
.72 |
.63 |
.65 |
.55 |
.70 |
|
Plcb3 |  |
NM_008874 |
phospholipase C, beta 3 (Plcb3), mRNA [NM_008874] |
KLA | 1.72 |
1.78 |
1.82 |
1.65 |
1.67 |
1.44 |
1.21 |
| ATP | .97 |
1.04 |
.81 |
.87 |
.78 |
.88 |
.94 |
| KLA/ATP | 1.69 |
1.89 |
1.44 |
1.66 |
1.12 |
.73 |
.93 |
|
Plcb4 |  |
AK082509 |
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230058B11 product:unclassifiable, full insert sequence. [AK082509] |
KLA | 1.06 |
1.03 |
.97 |
.98 |
1.02 |
1.01 |
.99 |
| ATP | .99 |
1.07 |
1.09 |
.95 |
.97 |
.97 |
1.02 |
| KLA/ATP | .98 |
1.00 |
1.03 |
.96 |
1.02 |
.91 |
.98 |
|
Plcb4 |  |
NM_013829 |
phospholipase C, beta 4 (Plcb4), mRNA [NM_013829] |
KLA | .88 |
.94 |
.81 |
.82 |
.81 |
.86 |
1.01 |
| ATP | 1.00 |
1.01 |
.92 |
.93 |
.88 |
.85 |
.89 |
| KLA/ATP | .97 |
.94 |
.78 |
.80 |
.78 |
.86 |
.97 |
|
Ppp2ca |  |
NM_019411 |
protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform (Ppp2ca), mRNA [NM_019411] |
KLA | 1.17 |
1.13 |
1.18 |
1.20 |
1.54 |
1.45 |
1.34 |
| ATP | 1.09 |
1.20 |
1.07 |
1.33 |
1.56 |
2.04 |
1.43 |
| KLA/ATP | 1.14 |
1.17 |
1.15 |
1.49 |
1.59 |
2.37 |
2.02 |
|
Ppp2cb |  |
NM_017374 |
protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform (Ppp2cb), mRNA [NM_017374] |
KLA | 1.32 |
1.33 |
1.37 |
1.24 |
1.27 |
1.09 |
1.18 |
| ATP | .94 |
.93 |
.82 |
.91 |
1.22 |
2.01 |
1.08 |
| KLA/ATP | 1.24 |
1.14 |
.80 |
.97 |
1.13 |
1.54 |
1.18 |
|
Ppp2r1a |  |
NM_016891 |
protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), alpha isoform (Ppp2r1a), mRNA [NM_016891] |
KLA | 1.44 |
1.39 |
1.47 |
1.37 |
1.69 |
1.33 |
1.16 |
| ATP | 1.18 |
1.55 |
.85 |
1.67 |
1.38 |
.99 |
1.24 |
| KLA/ATP | 1.66 |
1.98 |
.97 |
2.33 |
1.41 |
1.65 |
1.38 |
|
Ppp2r1b |  |
NM_001034085 |
protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform (Ppp2r1b), transcript variant 1, mRNA [NM_001034085] |
KLA | 1.26 |
1.17 |
1.14 |
1.13 |
1.12 |
1.11 |
.99 |
| ATP | .90 |
.90 |
.96 |
.98 |
1.59 |
1.71 |
1.16 |
| KLA/ATP | 1.23 |
1.16 |
.99 |
1.00 |
1.54 |
1.34 |
1.24 |
|
Ppp2r1b |  |
NM_028614 |
protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform (Ppp2r1b), transcript variant 2, mRNA [NM_028614] |
KLA | 2.38 |
2.38 |
2.53 |
1.80 |
1.52 |
.95 |
1.16 |
| ATP | 1.17 |
1.29 |
1.04 |
1.09 |
1.16 |
1.19 |
1.00 |
| KLA/ATP | 2.59 |
2.78 |
1.82 |
2.31 |
1.34 |
1.03 |
.75 |
|
Prkca |  |
NM_011101 |
protein kinase C, alpha (Prkca), mRNA [NM_011101] |
KLA | 1.00 |
.96 |
.94 |
.95 |
.95 |
.89 |
.96 |
| ATP | 1.00 |
1.03 |
.91 |
.94 |
.82 |
.87 |
1.13 |
| KLA/ATP | 1.02 |
.95 |
.91 |
.86 |
.78 |
.84 |
.94 |
|
Prkcb1 |  |
NM_008855 |
protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] |
KLA | .92 |
.95 |
.93 |
.78 |
.77 |
1.08 |
1.83 |
| ATP | 1.03 |
1.12 |
1.09 |
1.23 |
.90 |
2.08 |
.96 |
| KLA/ATP | .98 |
.99 |
.82 |
.89 |
.62 |
1.01 |
1.08 |
|
Prkcc |  |
NM_011102 |
protein kinase C, gamma (Prkcc), mRNA [NM_011102] |
KLA | 1.02 |
1.04 |
1.11 |
1.04 |
.96 |
1.02 |
1.05 |
| ATP | .98 |
.98 |
1.05 |
1.03 |
1.08 |
.96 |
.95 |
| KLA/ATP | 1.21 |
1.16 |
1.09 |
1.07 |
1.04 |
.98 |
.93 |
|
Prkg1 |  |
NM_011160 |
protein kinase, cGMP-dependent, type I (Prkg1), transcript variant 2, mRNA [NM_011160] |
KLA | .97 |
.96 |
.97 |
1.08 |
1.11 |
.93 |
.94 |
| ATP | 1.07 |
.96 |
.94 |
.99 |
1.03 |
1.60 |
.90 |
| KLA/ATP | .95 |
1.07 |
1.00 |
1.04 |
1.00 |
1.04 |
.91 |
|
Prkg2 |  |
NM_008926 |
protein kinase, cGMP-dependent, type II (Prkg2), mRNA [NM_008926] |
KLA | .97 |
1.03 |
1.03 |
1.02 |
1.15 |
.99 |
.98 |
| ATP | 1.02 |
1.08 |
.98 |
.98 |
1.00 |
1.00 |
1.02 |
| KLA/ATP | 1.01 |
1.02 |
1.03 |
.97 |
1.00 |
.93 |
1.02 |
|
Raf1 |  |
AK036317 |
16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] |
KLA | 1.47 |
1.34 |
1.55 |
1.29 |
1.59 |
1.32 |
1.46 |
| ATP | 1.05 |
.98 |
.54 |
.63 |
3.32 |
2.07 |
1.01 |
| KLA/ATP | 1.57 |
1.33 |
.79 |
.96 |
2.26 |
1.38 |
1.35 |
|
Raf1 |  |
NM_029780 |
v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] |
KLA | 1.65 |
1.64 |
1.93 |
1.77 |
1.77 |
1.72 |
1.81 |
| ATP | .95 |
.96 |
.83 |
.80 |
2.22 |
2.92 |
1.19 |
| KLA/ATP | 1.68 |
1.64 |
1.39 |
1.32 |
1.85 |
2.50 |
2.06 |
|
Ryr1 |  |
AK042482 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630095L05 product:RYANODINE RECEPTOR 1 (SKELETAL MUSCLE-TYPE RYANODINE RECEPTOR) (RYR1) (RYR-1) (SKELETAL MUSCLE CALCIUM RELEASE CHANNEL) homolog [Homo sapiens], full |
KLA | 1.61 |
1.64 |
1.65 |
1.73 |
1.85 |
1.62 |
1.13 |
| ATP | 1.05 |
1.11 |
1.16 |
1.42 |
1.40 |
1.28 |
1.22 |
| KLA/ATP | 1.77 |
1.70 |
1.98 |
2.23 |
1.96 |
1.47 |
1.48 |
|
Ryr1 |  |
AK042482 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630095L05 product:RYANODINE RECEPTOR 1 (SKELETAL MUSCLE-TYPE RYANODINE RECEPTOR) (RYR1) (RYR-1) (SKELETAL MUSCLE CALCIUM RELEASE CHANNEL) homolog [Homo sapiens], full i |
KLA | 1.52 |
1.58 |
1.63 |
1.69 |
1.73 |
1.53 |
1.25 |
| ATP | .99 |
.99 |
1.07 |
1.37 |
1.35 |
1.30 |
1.15 |
| KLA/ATP | 1.58 |
1.67 |
1.84 |
1.97 |
1.94 |
1.65 |
1.41 |
|
Ryr1 |  |
NM_009109 |
ryanodine receptor 1, skeletal muscle (Ryr1), mRNA [NM_009109] |
KLA | .94 |
.93 |
.89 |
.91 |
.82 |
.86 |
.88 |
| ATP | 1.05 |
.98 |
.95 |
1.08 |
1.41 |
1.28 |
1.15 |
| KLA/ATP | .93 |
.95 |
.92 |
1.02 |
1.62 |
1.96 |
2.06 |
|